AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26669919
Drug: Ixekizumab 160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixekizumab 160 mg administered at weeks 16, 18, and 20, then every 4 weeks through Week 64
Trial: 23778432
Drug: Red blood
RxNorm normalized name: Red blood cells
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red blood cell transfusion (when initial hemoglobin > 10 g/dL)
Trial: 11016286
Drug: Active laser
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active laser treatment (50 mW, 830 nm, 10 minutes per session)
Trial: 31571834
Drug: Test FDC
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test FDC tablet containing 10 mg melitracen and 0.5 mg flupentixol
Trial: 31571834
Drug: Reference FDC
RxNorm normalized name: DYE FDC BLUE #1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference FDC tablet containing 10 mg melitracen and 0.5 mg flupentixol
Trial: 30376823
Drug: Weekly cell
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly cell phone counselling and daily text messages
Trial: 25271822
Drug: Dexamphetamine sulfate
RxNorm normalized name: Dexamphetamine sulfate
DrugBank: Dextroamphetamine (DB01576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamphetamine sulfate (0.3 mg/kg) administered intravenously
Trial: 17968992
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone (2 mg/kg/day in 3 divided doses for 3 days)
Trial: 16221106
Drug: Losartan plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan plus conventional therapy (CT)
Trial: 16221106
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (CT) alone
Trial: 12602521
Drug: Oral and
RxNorm normalized name: Tridate, oral and rectal kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral and parenteral L-ornithine-L-aspartate (OA)
Trial: 12602521
Drug: Oral L-ornithine-L-aspartate
RxNorm normalized name: ornithine, (L)-isomer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral L-ornithine-L-aspartate (OA)
Trial: 12602521
Drug: Intravenous L-ornithine-L-aspartate
RxNorm normalized name: ornithine, (L)-isomer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous L-ornithine-L-aspartate (OA)
Trial: 2491458
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg omeprazole daily
Trial: 590310
Drug: 14C‐aminopyrine 9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14C‐aminopyrine 9 mg/kg (pharmacological dose)
Trial: 30842115
Drug: Duloxetine 30
RxNorm normalized name: duloxetine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 30 mg
Trial: 25989213
Drug: Forsus Fatigue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Forsus Fatigue Resistant Device (FFRD) and mini-implants (FMI)
Trial: 22743148
Drug: Cabazitaxel 25
RxNorm normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cabazitaxel 25 mg/m²
Trial: 22743148
Drug: Mitoxantrone 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitoxantrone 12 mg/m²
Trial: 19627577
Drug: Inappropriate medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inappropriate medication use (long-acting benzodiazepines)
Trial: 19627577
Drug: Inappropriate medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inappropriate medication use (other inappropriate psychotropics)
Trial: 19627577
Drug: Inappropriate medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inappropriate medication use (medications with anticholinergic properties)
Trial: 17560254
Drug: Routine oral
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine oral calcitriol and calcium carbonate postoperatively (Group 1)
Trial: 9331015
Drug: Candesartan cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Candesartan cilexetil 8‐16 mg once‐daily
Trial: 31957152
Drug: Topical minoxidil
RxNorm normalized name: MINOXIDIL 50 mg in 1 mL TOPICAL SOLUTION [Stafenit Hair Regrowth Treatment Topical Minoxidil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical minoxidil 2%
Trial: 3319731
Drug: Topical minoxidil
RxNorm normalized name: MINOXIDIL 50 mg in 1 mL TOPICAL SOLUTION [Stafenit Hair Regrowth Treatment Topical Minoxidil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical minoxidil 2% and Placebo
Trial: 29800250
Drug: LV rehabilitation
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LV rehabilitation (low-vision devices with therapy)
Trial: 29800250
Drug: Basic LV
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic LV services (low-vision devices without therapy)
Trial: 20332484
Drug: Surgery plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery plus 5-fluorouracil (5-FU)-based adjuvant chemotherapy
Trial: 15806211
Drug: Intranasal budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intranasal budesonide (BUD) 200 microg twice daily
Trial: 15806211
Drug: Oral choline
RxNorm normalized name: choline Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral choline (tricholine citrate, TRI) 500 mg thrice daily
Trial: 7822663
Drug: MK-0591 (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0591 (3 oral doses of 250 mg each at 24, 12, and 1.5 hours before allergen inhalation)
Trial: 2793717
Drug: Metabolic alkalosis
RxNorm normalized name: ALK-4290
DrugBank: ALK-4290 (DB15269)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metabolic alkalosis induced by oral administration of NaHCO3
Trial: 31033610
Drug: Topical glyceryl
RxNorm normalized name: glyceryl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical glyceryl trinitrate patch plus eccentric training
Trial: 29060739
Drug: Game-assisted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Game-assisted therapy and conventional therapy
Trial: 23271794
Drug: Dabigatran etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dabigatran etexilate 110 mg BID
Trial: 23271794
Drug: Dabigatran etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dabigatran etexilate 150 mg BID
Trial: 20705951
Drug: LPV/r (400mg/100mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPV/r (400mg/100mg) + BILR 355 (150 mg)
Trial: 20705951
Drug: BILR 355/r
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BILR 355/r (150 mg/100mg)
Trial: 17958625
Drug: Oral amoxicillin
RxNorm normalized name: amoxicillin Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral amoxicillin (50 mg/kg per day)
Trial: 15636137
Drug: Bacterial polycomponent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacterial polycomponent vaccine (VP‐4)
Trial: 9479761
Drug: Sequential condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential condition (tone offset coinciding with noise onset)
Trial: 4921221
Drug: Prednisone therapy
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone therapy in Stage I sarcoidosis
Trial: 31951780
Drug: Booster dose
RxNorm normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster dose of polygeline-free inactivated TBE vaccine (Encepur Adults, GSK) administered approximately 3 years post-primary vaccination.
Trial: 24332196
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg ivabradine
Trial: 24332196
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg ivabradine
Trial: 24332196
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg ivabradine
Trial: 21710403
Drug: No-dose-reduction group
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-dose-reduction group (initial optimal therapeutic doses continued throughout the study)
Trial: 21710403
Drug: 4-week group
RxNorm normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-week group (initial optimal therapeutic doses continued for 4 weeks followed by a half dose reduction)
Trial: 21710403
Drug: 26-week group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 26-week group (initial optimal therapeutic doses continued for 26 weeks followed by a half dose reduction)
Trial: 19131370
Drug: Cilostazol 100mg
RxNorm normalized name: CILOSTAZOL 100MG TAB
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cilostazol 100mg twice a day
Trial: 11280845
Drug: Chemotherapy regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy regimen A
Trial: 11280845
Drug: Chemotherapy regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy regimen B
Trial: 9263085
Drug: Eltanolone (0.41
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltanolone (0.41 +/- 0.1 mg/kg)
Trial: 9263085
Drug: Thiopental (2.88
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental (2.88 +/- 0.62 mg/kg)
Trial: 9263085
Drug: Etomidate (0.26
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etomidate (0.26 +/- 0.06 mg/kg)
Trial: 2963759
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide acetate plus oral placebo (group A, n = 7)
Trial: 2963759
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide acetate plus oral medroxyprogesterone acetate (group B, n = 9)
Trial: 26268804
Drug: Mass Drug
RxNorm normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mass Drug Administration (MDA) with dihydroartemisinin plus piperaquine (DHAp)
Trial: 26268804
Drug: Focal Mass
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Focal Mass Drug Administration (fMDA) with dihydroartemisinin plus piperaquine (DHAp)
Trial: 26268804
Drug: No mass
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No mass treatment (standard of care)
Trial: 16787512
Drug: Timcodar dimesylate
RxNorm normalized name: Timcodar
DrugBank: Timcodar (DB12761)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timcodar dimesylate 12.5 mg/day
Trial: 16787512
Drug: Timcodar dimesylate
RxNorm normalized name: Timcodar
DrugBank: Timcodar (DB12761)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timcodar dimesylate 50 mg/day
Trial: 14504873
Drug: Rofecoxib 50
RxNorm normalized name: rofecoxib 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib 50 mg 1 h before operation (group R)
Trial: 14504873
Drug: Naproxen sodium
RxNorm normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen sodium 550 mg 1 h before surgery (group N)
Trial: 10865480
Drug: Otomize ear
RxNorm normalized name: Atomic Balm
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Otomize ear spray
Trial: 9108642
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg b.i.d. sodium valproate (VPA)
Trial: 9108642
Drug: 1,000 mg
RxNorm normalized name: bran 1,000 mg ORAL WAFER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 mg b.i.d. sodium valproate (VPA)
Trial: 9108642
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of sodium valproate (VPA)
Trial: 8474201
Drug: HA-1A (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HA-1A (10 mg.kg-1)
Trial: 8474201
Drug: Control (human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (human IgM antibody 10 mg.kg-1 and human serum albumin)
Trial: 8474201
Drug: Control human
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control human IgM antibody
Trial: 24588407
Drug: Multisystemic Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multisystemic Therapy adapted for health care settings (MST‐HC)
Trial: 21813900
Drug: Short-acting beta
RxNorm normalized name: Short-acting sulfonamides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-acting beta agonists
Trial: 21813900
Drug: Long-acting bronchodilators
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting bronchodilators
Trial: 14564337
Drug: Transdermal nitroglycerin
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerin patch (15 mg/24 hours)
Trial: 11109297
Drug: Intermittent (premenstrual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent (premenstrual only) treatment with SSRIs
Trial: 8866346
Drug: Tagetes patula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tagetes patula preparations plus protective pad
Trial: 1471435
Drug: Comprehensive team
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comprehensive team care (CC)
Trial: 6318224
Drug: Enalapril (5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (5, 10 and 20 mg twice daily)
Trial: 6318224
Drug: Propranolol (40,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (40, 80 and 120 mg twice daily)
Trial: 30420001
Drug: In-treatment expectancy
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-treatment expectancy during antidepressant treatment
Trial: 30420001
Drug: Gap between
RxNorm normalized name: GAP JUNCTION ALPHA-3 PROTEIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gap between expected treatment outcomes and actual depressive severity
Trial: 26813890
Drug: Long-chain n-3
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-chain n-3 polyunsaturated fatty acids intake meeting the recommendation (≥500 mg/day)
Trial: 22891212
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of triglycerides plus heparin
Trial: 22891212
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of glycerol
Trial: 17000647
Drug: Continuous oral
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous oral progestin
Trial: 16277782
Drug: GOS/FOS formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GOS/FOS formula (6 g/l)
Trial: 7782965
Drug: Primary-surgical regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary-surgical regimen (Group A): total pharyngo‐laryngo‐esophagectomy after 20 Gy irradiation therapy. Chemotherapy was combined in some patients.
Trial: 7782965
Drug: Primary-radiotherapeutic regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary-radiotherapeutic regimen (Group B): radiation therapy (60 Gy) with chemotherapy (UFT 300 to 600 mg/day; some patients received 1-2 courses of intravenous cisplatinum).
Trial: 2109951
Drug: Urapidil (bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urapidil (bolus injections of 25, 25 and 50 mg, followed by an infusion of 180 ml/h)
Trial: 6106469
Drug: Pindolol (beta-blocking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol (beta-blocking drug)
Trial: 19936457
Drug: Intracoronary injection
RxNorm normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary injection of 100 x 10^6 mononuclear cells (Arterial Group)
Trial: 19936457
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of 100 x 10^6 mononuclear cells (Venous Group)
Trial: 16253719
Drug: Erythropoietin alfa
RxNorm normalized name: RECOMBINANT HUMAN ERYTHROPOIETIN ALFA
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin alfa treatment group (n=78), median final dose 2,000 IU/wk
Trial: 16253719
Drug: Control/delayed treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control/delayed treatment group (n=94), median final dose 3,000 IU/wk
Trial: 16253719
Drug: Erythropoietin alfa
RxNorm normalized name: RECOMBINANT HUMAN ERYTHROPOIETIN ALFA
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin alfa treatment group
Trial: 7821104
Drug: Omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (20 mg/day) alone
Trial: 7821104
Drug: Omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (20 mg/day) plus plaunotol (240 mg/day)
Trial: 331994
Drug: Guanethidine 3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanethidine 3% - adrenaline 0.5% (G-A)
Trial: 16929421
Drug: 50 microg
RxNorm normalized name: Digoxin 250 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 microg oral misoprostol every 4 h (treatment group 1)
Trial: 16929421
Drug: 100 microg
RxNorm normalized name: Digoxin 100 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 microg oral misoprostol every 4 h (treatment group 2)
Trial: 16929421
Drug: Placebo (vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (vitamin B6 50 mg, control)
Trial: 12922104
Drug: Priming dose
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Priming dose of Avaxim pediatric hepatitis A vaccine given at 6 months of age (Group 2)
Trial: 12922104
Drug: Priming dose
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Priming dose of Avaxim pediatric hepatitis A vaccine given 2 weeks after routine vaccinations (Group 1)
Trial: 1294401
Drug: hCG (10,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hCG (10,000 IU i.m. on first diagnosis of pregnancy, 5000 IU twice weekly to week 12, then once weekly to week 16)
Trial: 29795527
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg tadalafil once a day
Trial: 29795527
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg tadalafil on-demand (four times a month)
Trial: 23322261
Drug: Alexander Technique
RxNorm normalized name: Nerium oleander flower
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alexander Technique (AT) with 12 weekly home-based lessons in addition to usual care
Trial: 23071635
Drug: Testosterone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone (50 mg transdermal administration)
Trial: 20191485
Drug: Anti-tumor necrosis
RxNorm normalized name: G 1 (anti-tumor agent)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-tumor necrosis factor therapy (exact dosage and duration not specified)
Trial: 7097422
Drug: Protein supplement
RxNorm normalized name: PROTEIN SUPPLEMENT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein supplement isolated from mature human milk, increasing protein content by 0.8 gm/dl
Trial: 29578832
Drug: Daily motivational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily motivational text messages, additional texted tips in response to keywords, and weekly study questions
Trial: 29578832
Drug: Weekly study
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly study questions only
Trial: 10440416
Drug: Clopidogrel 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 50 mg once daily
Trial: 20844075
Drug: 100% Concord
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100% Concord grape juice (7 mL · kg⁻¹ · d⁻¹)
Trial: 16094738
Drug: Sequential radical
RxNorm normalized name: Campsis radicans flower extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential radical radiotherapy and cisplatin-based chemotherapy
Trial: 12084743
Drug: Trabeculectomy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trabeculectomy with intraoperative antimetabolites (5‐fluorouracil 25 mg/ml, mitomycin C 0.2 mg/ml and 0.4 mg/ml)
Trial: 12084743
Drug: Viscocanalostomy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viscocanalostomy with intraoperative intracanalicular Healonid GV injection
Trial: 12084743
Drug: Viscocanalostomy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viscocanalostomy with balanced saline solution
Trial: 2296627
Drug: Moclobemide (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide (200 mg t.i.d.)
Trial: 2296627
Drug: Clomipramine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine (25 mg b.i.d.)
Trial: 2296627
Drug: Alcohol (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.6 g/l blood alcohol concentration)
Trial: 31090488
Drug: Ketamine (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.8 mg/kg mixed in juice, administered 30 minutes before procedure)